After Legend Biotech (LEGN) and partner Johnson and Johnson (JNJ) announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint, BTIG analyst Justin Zelin said the firm views this "highly anticipated readout" of the study "positively" and expects that Legend and J&J will commercialize Carvykti in earlier lines of therapy. The firm, which sees the news as a confirmatory event that supports Carvykti use in earlier lines against active standard of care comparator in "a robust phase 3 study," thinks this could "cement" a position as "a best-in-class autologous BCMA CAR-T therapy" in multiple myeloma. BTIG has a Buy rating and $75 price target on Legend shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LEGN:
- Piper keeps $78 target on Legend Biotech after Carvykti trial hits
- Legend Biotech says Carvykti myeloma study met primary endpoint
- Legend Biotech price target raised to $65 from $53 at Barclays
- Legend says China accepts ciltacabtagene New Drug Application
- Piper Sandler names three top biotechnology picks for 2023